A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs […]
The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division, appears to be well-tolerated with successful […]
A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia […]
Cancer drugs capable of weakening the body’s immune defenses are no more likely to increase the risk of COVID-19 infection or death than breast cancer therapies […]